STRO-001

Overview

STRO-001 is an antibody drug conjugate targeting CD74, a cell surface protein associated with B-cell malignancies, including non-Hodgkin lymphoma and multiple myeloma.

SparkCures ID 309
Developed By Sutro Biopharma, Inc.
Generic Name STRO-001
Treatment Classifications
Treatment Targets

Clinical Trials

Published Results

Interim Phase 1 Safety Data

June 15, 2019

  • Interim results show STRO-001 was generally well tolerated and anti-tumor activity was observed in two patients with recurrent diffuse large B-cell lymphoma (DLBCL)
Read More

Resources

There are no resources, links or videos to display for this treatment.